Loading...
Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study
Median survival times (STs) for doxorubicin-treated canine lymphoma range from 5.7 to 9 months. Because dogs treated with multi-agent protocols have longer STs, we sought to evaluate whether adding cyclophosphamide would improve outcome in canine lymphoma patients while maintaining an acceptable lev...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2010
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3129606/ https://ncbi.nlm.nih.gov/pubmed/20691026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5829.2010.00215.x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|